Authors:
Gazarian, M
Tugwell, P
Boers, M
Bombardier, C
Brooks, P
Day, R
Strand, V
Wells, G
Citation: M. Gazarian et al., Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT drug toxicity working party, J RHEUMATOL, 26(1), 1999, pp. 207-209
Authors:
Ortiz, Z
Shea, B
Dieguez, MG
Boers, M
Tugwell, P
Boonen, A
Wells, G
Citation: Z. Ortiz et al., The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials, J RHEUMATOL, 26(1), 1999, pp. 210-216
Authors:
Wells, G
Boers, M
Shea, B
Tugwell, P
Westhovens, R
Saurez-Almazor, M
Buchbinder, R
Citation: G. Wells et al., Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: Preliminary findings in the generic health OMERACT study, J RHEUMATOL, 26(1), 1999, pp. 217-221
Authors:
Verhagen, AP
de Vet, HCW
de Bie, RA
Kessels, AGH
Boers, M
Bouter, LM
Knipschild, PG
Citation: Ap. Verhagen et al., The delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus, J CLIN EPID, 51(12), 1998, pp. 1235-1241
Authors:
Giltay, EJ
Verhoeven, AC
van Schaardenburg, D
Popp-Snijders, C
Boers, M
Gooren, LJG
Dijkmans, BAC
Citation: Ej. Giltay et al., Serum dehydroepiandrosterone sulphate levels in patients with early rheumatoid arthritis: Positive association with C-reactive protein, but not with HLA-DR genotype, BR J RHEUM, 37(11), 1998, pp. 1254-1256